User profiles for "author:M Plante"
 | Michael PlanteResearch Economist, Federal Reserve Bank of Dallas Verified email at dal.frb.org Cited by 1071 |
Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature
M Plante, MC Renaud, H François, M Roy - Gynecologic oncology, 2004 - Elsevier
Objective. To review the oncological results and complication rate of our first consecutive 72
completed cases of vaginal radical trachelectomies (VRT). Methods. From October 1991 to …
completed cases of vaginal radical trachelectomies (VRT). Methods. From October 1991 to …
Vaginal radical trachelectomy: a valuable fertility-preserving option in the management of early-stage cervical cancer. A series of 50 pregnancies and review of the …
M Plante, MC Renaud, IA Hoskins, M Roy - Gynecologic oncology, 2005 - Elsevier
OBJECTIVE.: To report the obstetrical results following vaginal radical trachelectomy (VRT),
a fertility-preserving surgery in the treatment of early-stage cervical cancer. METHODS …
a fertility-preserving surgery in the treatment of early-stage cervical cancer. METHODS …
Sentinel node mapping with indocyanine green and endoscopic near-infrared fluorescence imaging in endometrial cancer. A pilot study and review of the literature
M Plante, O Touhami, XB Trinh, MC Renaud… - Gynecologic …, 2015 - Elsevier
Objectives Indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging is a new
tracer modality used for lymphatic mapping. We report our initial experience with ICG for …
tracer modality used for lymphatic mapping. We report our initial experience with ICG for …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
[HTML][HTML] A phase 3 trial of bevacizumab in ovarian cancer
…, F Selle, MR Mirza, A Leminen, M Plante… - … England Journal of …, 2011 - Mass Medical Soc
Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, S Williams, J Cosin, J Hoffman, M Plante… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
Background The ICON7 trial previously reported improved progression-free survival in
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, S Banerjee, J Cosin, J Hoffman, M Plante… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
…, P Vuylsteke, H Hirte, S Mahner, M Plante… - The lancet …, 2015 - thelancet.com
Background The poly (ADP-ribose) polymerase inhibitor olaparib has shown antitumour
activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with …
activity in patients with platinum-sensitive, recurrent, high-grade serous ovarian cancer with …
Inefficient clearance of myelin debris by microglia impairs remyelinating processes
A Lampron, A Larochelle, N Laflamme… - Journal of Experimental …, 2015 - rupress.org
An imbalance between remyelinating and demyelinating rates underlies degenerative
processes in demyelinating diseases such as multiple sclerosis. An optimal therapeutic …
processes in demyelinating diseases such as multiple sclerosis. An optimal therapeutic …